4 news items
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GOSS
7 May 24
or inadequate efficacy of seralutinib that may limit their development, regulatory approval and/or commercialization, or may result in clinical holds, recalls
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
its development, regulatory approval and/or commercialization, or may result in clinical holds, recalls or product liability claims; Gossamer's ability
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
GOSS
3 May 24
efficacy of seralutinib that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
GOSS
5 Mar 24
, or may result in clinical holds, recalls or product liability claims; Gossamer's ability to obtain and maintain intellectual property protection
- Prev
- 1
- Next